secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2023-07-27T23:59:59+00:00
Accession:  0001104659-23-084538
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mersana Therapeutics fails Phase 2 UPLIFT trial; cuts workforce 50% and shifts focus to next-gen ADC platforms
--------------------------------------------------------------------------------

- UPLIFT trial of UpRi in platinum-resistant ovarian cancer missed primary endpoint; ORR 15.6% in NaPi2b-positive patients (95% CI: 10.0%-22.7%).
- Company to discontinue UpRi development, wind down related trials (UP-NEXT, UPGRADE-A), and reduce staffing by ~50%.
- Preliminary cash balance of $286.6M as of June 30, 2023; expects funds to support operating plan into 2026.
- Focus shifts to next-generation ADC platforms Dolasynthen and Immunosynthen; plans to advance XMT-1660 and address XMT-2056 clinical hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/0001104659-23-084538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/tm2322196d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-084538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer